- Home
- REVB vs SONN Comparison
REVB vs SONN Comparison
Compare REVB & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- SONN
- Stock Information
- Founded
- REVB 2020
- SONN N/A
- Country
- REVB United States
- SONN United States
- Employees
- REVB N/A
- SONN N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- SONN Health Care
- Exchange
- REVB Nasdaq
- SONN Nasdaq
- Market Cap
- REVB 3.8M
- SONN 3.8M
- IPO Year
- REVB N/A
- SONN N/A
- Fundamental
- Price
- REVB $2.38
- SONN $3.26
- Analyst Decision
- REVB
- SONN Strong Buy
- Analyst Count
- REVB 0
- SONN 1
- Target Price
- REVB N/A
- SONN $20.00
- AVG Volume (30 Days)
- REVB 283.8K
- SONN 11.6M
- Earning Date
- REVB 08-08-2025
- SONN 08-13-2025
- Dividend Yield
- REVB N/A
- SONN N/A
- EPS Growth
- REVB N/A
- SONN N/A
- EPS
- REVB N/A
- SONN N/A
- Revenue
- REVB N/A
- SONN $1,000,000.00
- Revenue This Year
- REVB N/A
- SONN $5,376.22
- Revenue Next Year
- REVB N/A
- SONN N/A
- P/E Ratio
- REVB N/A
- SONN N/A
- Revenue Growth
- REVB N/A
- SONN 978.39
- 52 Week Low
- REVB $2.11
- SONN $1.08
- 52 Week High
- REVB $168.00
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- REVB 34.09
- SONN 43.00
- Support Level
- REVB $2.97
- SONN $3.83
- Resistance Level
- REVB $3.18
- SONN $4.38
- Average True Range (ATR)
- REVB 0.22
- SONN 1.92
- MACD
- REVB 0.05
- SONN -0.50
- Stochastic Oscillator
- REVB 7.14
- SONN 0.99
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.